Epigenetic drug discovery and tools
 

Management and Board

Management

 

    Barrie Ward   Executive Chairman
    Will West   Chief Executive
    Tim Fell  Chief Operating Officer
    David Knowles  Chief Scientific Officer
    Nessa Carey  Scientific Director
    Neil Pegg Director of Discovery Research
    Jonathan Best Programme Manager
    Dev Crease  Patent Counsel
    Richard Brooks Finance Director
    Thea Stanway  Finance Officer

  

Board

 

    Barrie Ward  Executive Chairman
    Will West  Executive Director
    Tim Fell Executive Director
    David Knowles Executive Director
    Gerald Chan Non-Executive Director
    Sue Foden Non-Executive Director
    Dan Roach Non-Executive Director
    David Secher Non-Executive Director
    Azim Surani Board Observer

 

Barrie Ward (Executive Chairman)   Board member

Barrie WardBarrie Ward holds a BSc and PhD in microbial biochemistry from the University of Bath. From 1984-94 Barrie served as Director of the Microbiology Division of Glaxo Research and Development, with responsibility for infectious disease research.  He was appointed Chairman and CEO of Virus Research Institute Inc., which in 1998 merged with T-Cell Sciences Inc. to form AVANT Immunotherapeutics Inc. 

 

In 1999 Barrie became Chief Executive Officer of KuDOS Pharmaceuticals Limited and served until January 2006 when the company was acquired by AstraZeneca.  KuDOS was focused on the discovery and development of inhibitors of DNA repair as new treatments for cancer.  Barrie is currently on the boards of Spirogen, Onyvax, Cancer Research Technology, Pharming Group N.V. and Biotica. He became Chairman of CellCentric in April 2006.